HydrALAZINE HCl Injection recalled over manufacturing violations
- Recall date
- April 26, 2023
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Akorn, Inc. recalls HydrALAZINE HCl Injection, USP, 20 mg/mL, 1 mL Single Dose vials, For Intramuscular or Intravenous Use, Rx Only, Manufa…
- Recall number
- D-0809-2023
- FDA classification
- Class II
- Brand / firm
- Akorn, Inc.
- Sold / distributed
- Nationwide in the USA and Puerto Rico
Why it was recalled
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
HydrALAZINE HCl Injection, USP, 20 mg/mL, 1 mL Single Dose vials, For Intramuscular or Intravenous Use, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs
Get recall alerts
Free email alert whenever Akorn, Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Akorn, Inc.